PMID- 34804178 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211123 IS - 1741-427X (Print) IS - 1741-4288 (Electronic) IS - 1741-427X (Linking) VI - 2021 DP - 2021 TI - The Effect of Curcuma longa on Inflammatory Mediators and Immunological, Oxidant, and Antioxidant Biomarkers in Asthmatic Rats. PG - 4234326 LID - 10.1155/2021/4234326 [doi] LID - 4234326 AB - The effects of Curcuma longa (C. longa) on total and differential WBC, inflammatory and immunologic mediators, and oxidant and antioxidant biomarkers in bronchoalveolar lavage fluid (BALF) of rats model of asthma were assessed. Animals were divided to 5 groups including control (C), asthma (sensitized to ovalbumin), and asthmatic groups treated with 0.75, 1.50, and 3.00 mg/ml C. longa (CL) and 1.25 mug/ml dexamethasone (D) (8 rats in each group). Total and differential WBC count, concentrations of phospholipase A(2) (PLA(2)), total protein (TP), interferon-gamma (IFN-gamma), interleukin-4 (IL-4), immunoglobulin E (IgE), NO(2), NO(3), malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and thiol in BALF were assessed. Total and most differential WBC counts and BALF levels of PLA(2), TP, IgE, IL-4, and oxidants in asthma group were higher but antioxidants and IFN-gamma levels as well as IFN-gamma/IL-4 ratio were lower than control group (p < 0.001 for all cases). Total WBC and levels of PLA(2), IgE, NO(2), and NO(3) were significantly reduced following treatment with C. longa, compared to asthma group (p < 0.001 for all cases). In groups treated with dexamethasone and two higher concentrations of C. longa, neutrophil and eosinophil counts as well as TP, IL-4, and MDA levels were significantly decreased but IFN-gamma, IFN-gamma/IL-4 ratio, and antioxidants were increased (except IFN-gamma/IL-4 ratio), compared to asthma group (p < 0.05 to p < 0.001). Compared to dexamethasone, C. longa exerted more pronounced effects on lung inflammation, oxidative stress, and immune system in asthmatic rats. CI - Copyright (c) 2021 Mohammad Hossein Boskabady et al. FAU - Boskabady, Mohammad Hossein AU - Boskabady MH AD - Neurogeneic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. AD - Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Amin, Fatemeh AU - Amin F AUID- ORCID: 0000-0003-0961-7667 AD - Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. AD - Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. FAU - Shakeri, Farzaneh AU - Shakeri F AUID- ORCID: 0000-0003-4813-6030 AD - Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran. AD - Department of Physiology and Pharmacology, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. LA - eng PT - Journal Article DEP - 20211112 PL - United States TA - Evid Based Complement Alternat Med JT - Evidence-based complementary and alternative medicine : eCAM JID - 101215021 PMC - PMC8604592 COIS- The authors disclose no conflicts of interest. EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 PMCR- 2021/11/12 CRDT- 2021/11/22 06:42 PHST- 2021/05/01 00:00 [received] PHST- 2021/10/04 00:00 [revised] PHST- 2021/10/13 00:00 [accepted] PHST- 2021/11/22 06:42 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] PHST- 2021/11/12 00:00 [pmc-release] AID - 10.1155/2021/4234326 [doi] PST - epublish SO - Evid Based Complement Alternat Med. 2021 Nov 12;2021:4234326. doi: 10.1155/2021/4234326. eCollection 2021.